Skip to main content
Top
Published in: World Journal of Surgery 4/2014

01-04-2014

Electrochemotherapy Treatment of Locally Advanced and Metastatic Soft Tissue Sarcomas: Results of a Non-Comparative Phase II Study

Authors: Luca G. Campana, Giuseppe Bianchi, Simone Mocellin, Sara Valpione, Laura Campanacci, Antonella Brunello, Davide Donati, Elisabetta Sieni, Carlo R. Rossi

Published in: World Journal of Surgery | Issue 4/2014

Login to get access

Abstract

Aims

Our aim was to evaluate the activity, toxicity, and feasibility of electrochemotherapy (ECT) in patients with soft-tissue sarcomas (STS).

Methods

A two-stage phase II trial was conducted between October 2006 and March 2012. Patients (N = 34) with locally advanced or metastatic STS, unsuitable for standard oncological treatments and with maximum 3-cm deep tumors, received an intravenous bolus of bleomycin (15,000 IU/m2), followed by tumor electroporation according to the European Standard Operating Procedures of ECT. Outcome measures included local response according to response evaluation criteria in solid tumors (RECIST), toxicity and tumor control. Feasibility measures included the accuracy of electrode placement and the intensity of electric current flowing in tumor tissue.

Results

Median tumor size was 4.0 cm (range 2–12). Objective response, assessed on 71 target lesions, was 92.2 % (complete 32.3, 95 % CI 28–64). A total of 15 patients received up to four cycles due to incomplete response, but re-treatment did not significantly improve outcome (p = 0.205). After a median follow-up of 19.3 months, 2-year local control rate was 72.5 %. Median time to local failure (N = 11 patients) was 5.1 months. Tumor response (p = 0.041) and control (p = 0.047) correlated with histological grading. Relevant toxicity consisted of G3 skin ulceration and soft tissue necrosis (35 and 23 % of patients, respectively), although this was manageable on an outpatient basis. The accuracy of electrode placement was 47.1 %, and the adequacy of electroporative current 85.3 %.

Conclusions

ECT may represent an active and safe treatment to achieve local control in advanced STS patients with symptomatic disease. Future research challenges include the improvement of electrode placement and voltage delivery together with the containment of soft tissue toxicity.
Appendix
Available only for authorised users
Literature
1.
go back to reference Karavasilis V, Seddon BM, Ashley S, Al-Muderis O, Fisher C, Judson I (2008) Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients. Cancer 112:1585–1591PubMedCrossRef Karavasilis V, Seddon BM, Ashley S, Al-Muderis O, Fisher C, Judson I (2008) Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients. Cancer 112:1585–1591PubMedCrossRef
2.
go back to reference Mir LM, Morsli N, Garbay JR, Billard V, Robert C, Marty M (2003) Electrochemotherapy: a new treatment of solid tumors. J Exp Clin Cancer Res 22:145–148PubMed Mir LM, Morsli N, Garbay JR, Billard V, Robert C, Marty M (2003) Electrochemotherapy: a new treatment of solid tumors. J Exp Clin Cancer Res 22:145–148PubMed
3.
go back to reference Belehradek M, Domenge C, Luboinski B, Orlowski S, Belehradek J Jr, Mir LM (1993) Electrochemotherapy, a new antitumour treatment. First clinical phase I-II trial. Cancer 72:3694–3700PubMedCrossRef Belehradek M, Domenge C, Luboinski B, Orlowski S, Belehradek J Jr, Mir LM (1993) Electrochemotherapy, a new antitumour treatment. First clinical phase I-II trial. Cancer 72:3694–3700PubMedCrossRef
4.
go back to reference Gehl J, Geertsen PF (2000) Efficient palliation of haemorrhaging malignant melanoma skin metastases by electrochemotherapy. Melanoma Res 10:585–589PubMedCrossRef Gehl J, Geertsen PF (2000) Efficient palliation of haemorrhaging malignant melanoma skin metastases by electrochemotherapy. Melanoma Res 10:585–589PubMedCrossRef
5.
go back to reference Byrne CM, Thompson JF, Johnston H, Hersey P, Quinn MJ, Michael Hughes T et al (2005) Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy). Melanoma Res 15:45–51PubMedCrossRef Byrne CM, Thompson JF, Johnston H, Hersey P, Quinn MJ, Michael Hughes T et al (2005) Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy). Melanoma Res 15:45–51PubMedCrossRef
6.
go back to reference Heller R, Gilbert R, Jaroszeski MJ (1999) Clinical applications of electrochemotherapy. Adv Drug Deliv Rev 35:119–129PubMedCrossRef Heller R, Gilbert R, Jaroszeski MJ (1999) Clinical applications of electrochemotherapy. Adv Drug Deliv Rev 35:119–129PubMedCrossRef
7.
go back to reference Mir LM, Devauchelle P, Quintin-Colonna F et al (1997) First clinical trial of cat soft-tissue sarcomas treatment by electrochemotherapy. Br J Cancer 76:1617–1622PubMedCrossRefPubMedCentral Mir LM, Devauchelle P, Quintin-Colonna F et al (1997) First clinical trial of cat soft-tissue sarcomas treatment by electrochemotherapy. Br J Cancer 76:1617–1622PubMedCrossRefPubMedCentral
8.
go back to reference Hyacinthe M, Jaroszeski MJ, Dang VV et al (1999) Electrically enhanced drug delivery for the treatment of soft tissue sarcoma. Cancer 85:409–417PubMedCrossRef Hyacinthe M, Jaroszeski MJ, Dang VV et al (1999) Electrically enhanced drug delivery for the treatment of soft tissue sarcoma. Cancer 85:409–417PubMedCrossRef
9.
go back to reference Horiuchi A, Nikaido T, Mitsushita J et al (2000) Enhancement of antitumour effect of bleomycin by low-voltage in vivo electroporation: a study of human uterine leiomyosarcomas in nude mice. Int J Cancer 88:640–644PubMedCrossRef Horiuchi A, Nikaido T, Mitsushita J et al (2000) Enhancement of antitumour effect of bleomycin by low-voltage in vivo electroporation: a study of human uterine leiomyosarcomas in nude mice. Int J Cancer 88:640–644PubMedCrossRef
10.
go back to reference Sersa G, Jarm T, Kotnik T et al (2008) Vascular disrupting action of electroporation and electrochemotherapy with bleomycin in murine sarcoma. Br J Cancer 98:388–398PubMedCrossRefPubMedCentral Sersa G, Jarm T, Kotnik T et al (2008) Vascular disrupting action of electroporation and electrochemotherapy with bleomycin in murine sarcoma. Br J Cancer 98:388–398PubMedCrossRefPubMedCentral
11.
go back to reference Shimizu T, Nikaido T, Gomyo H et al (2003) Electrochemotherapy for digital chondrosarcoma. J Orthop Sci 8:248–251PubMedCrossRef Shimizu T, Nikaido T, Gomyo H et al (2003) Electrochemotherapy for digital chondrosarcoma. J Orthop Sci 8:248–251PubMedCrossRef
12.
go back to reference de Bree R, Tijink BM, van Groeningen CJ, Leemans CR (2006) Electroporation therapy in soft tissue sarcoma: a potentially effective novel treatment. Sarcoma 85234. doi:10.1155/SRCM/2006/85234 de Bree R, Tijink BM, van Groeningen CJ, Leemans CR (2006) Electroporation therapy in soft tissue sarcoma: a potentially effective novel treatment. Sarcoma 85234. doi:10.​1155/​SRCM/​2006/​85234
13.
go back to reference Curatolo P, Quaglino P, Marenco F et al (2012) Electrochemotherapy in the treatment of Kaposi sarcoma cutaneous lesions: a two-center prospective phase II trial. Ann Surg Oncol 19:192–198PubMedCrossRef Curatolo P, Quaglino P, Marenco F et al (2012) Electrochemotherapy in the treatment of Kaposi sarcoma cutaneous lesions: a two-center prospective phase II trial. Ann Surg Oncol 19:192–198PubMedCrossRef
14.
go back to reference Latini A, Bonadies A, Trento E et al (2012) Effective treatment of Kaposi’s sarcoma by electrochemotherapy and intravenous bleomycin administration. Dermatol Ther 25:214–218PubMedCrossRef Latini A, Bonadies A, Trento E et al (2012) Effective treatment of Kaposi’s sarcoma by electrochemotherapy and intravenous bleomycin administration. Dermatol Ther 25:214–218PubMedCrossRef
15.
go back to reference Mir LM, Gehl J, Sersa G, Collins CG, Garbay JR, Billard V, Geertsen PF, Rudolf Z, O’Sullivan GC, Marty M (2006) Standard operating procedures of the electrochemotherapy: instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the Cliniporator by means of invasive or non-invasive electrodes. EJC Suppl 4:14–25CrossRef Mir LM, Gehl J, Sersa G, Collins CG, Garbay JR, Billard V, Geertsen PF, Rudolf Z, O’Sullivan GC, Marty M (2006) Standard operating procedures of the electrochemotherapy: instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the Cliniporator by means of invasive or non-invasive electrodes. EJC Suppl 4:14–25CrossRef
16.
go back to reference The EuroQoL Group (1990) EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 16:199–208CrossRef The EuroQoL Group (1990) EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 16:199–208CrossRef
17.
go back to reference Corovic S, Al Sakere B, Haddad V, Miklavcic D, Mir LM (2008) Importance of contact surface between electrodes and treated tissue in electrochemotherapy. Technol Cancer Res Treat 7:393–400PubMed Corovic S, Al Sakere B, Haddad V, Miklavcic D, Mir LM (2008) Importance of contact surface between electrodes and treated tissue in electrochemotherapy. Technol Cancer Res Treat 7:393–400PubMed
18.
go back to reference Marty M, Sersa G, Garbay J et al (2006) Electrochemotherapy—an easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. EJC Suppl 4:3–13CrossRef Marty M, Sersa G, Garbay J et al (2006) Electrochemotherapy—an easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. EJC Suppl 4:3–13CrossRef
19.
go back to reference Bryant J, Day R (1995) Incorporating toxicity considerations into the design of two-stage phase II clinical trials. Biometrics 51:1372–1383PubMedCrossRef Bryant J, Day R (1995) Incorporating toxicity considerations into the design of two-stage phase II clinical trials. Biometrics 51:1372–1383PubMedCrossRef
20.
go back to reference Miklavcic D, Beravs K, Semrov D, Cemazar M, Demsar F, Sersa G (1998) The importance of electric field distribution for effective in vivo electroporation of tissues. Biophys J 74(5):2152–2158PubMedCrossRefPubMedCentral Miklavcic D, Beravs K, Semrov D, Cemazar M, Demsar F, Sersa G (1998) The importance of electric field distribution for effective in vivo electroporation of tissues. Biophys J 74(5):2152–2158PubMedCrossRefPubMedCentral
21.
go back to reference Kos B, Zupanic A, Kotnik T, Snoj M, Sersa G, Miklavcic D (2010) Robustness of treatment planning for electrochemotherapy of deep-seated tumours. J Membr Biol 236:147–153PubMedCrossRef Kos B, Zupanic A, Kotnik T, Snoj M, Sersa G, Miklavcic D (2010) Robustness of treatment planning for electrochemotherapy of deep-seated tumours. J Membr Biol 236:147–153PubMedCrossRef
23.
go back to reference Deneve JL, Zager JS (2012) Isolated regional therapy for advanced extremity soft tissue sarcomas. Surg Oncol Clin N Am 21:287–299PubMedCrossRef Deneve JL, Zager JS (2012) Isolated regional therapy for advanced extremity soft tissue sarcomas. Surg Oncol Clin N Am 21:287–299PubMedCrossRef
24.
go back to reference Campana LG, Mocellin S, Basso M, Puccetti O, De Salvo GL, Chiarion-Sileni V et al (2009) Bleomycin-based electrochemotherapy: clinical outcome from a single institution’s experience with 52 patients. Ann Surg Oncol 16:191–199PubMedCrossRef Campana LG, Mocellin S, Basso M, Puccetti O, De Salvo GL, Chiarion-Sileni V et al (2009) Bleomycin-based electrochemotherapy: clinical outcome from a single institution’s experience with 52 patients. Ann Surg Oncol 16:191–199PubMedCrossRef
25.
go back to reference Campana LG, Valpione S, Falci C et al (2012) The activity and safety of electrochemotherapy in persistent chest wall recurrence from breast cancer after mastectomy: a phase-II study. Breast Cancer Res Treat 134:1169–1178PubMedCrossRef Campana LG, Valpione S, Falci C et al (2012) The activity and safety of electrochemotherapy in persistent chest wall recurrence from breast cancer after mastectomy: a phase-II study. Breast Cancer Res Treat 134:1169–1178PubMedCrossRef
27.
go back to reference Judson I, Verweij J, Gelderblom H et al (2012) Results of a randomised phase III trial (EORTC 62012) of single agent doxorubicin versus doxorubicin plus ifosfamide as first line chemotherapy for patients with advanced or metastatic soft tissue sarcoma: a survival study by the EORTC soft tissue and bone sarcoma group. Abstract LBA7. Ann Oncol. doi:10.1093/annonc/mds499 Judson I, Verweij J, Gelderblom H et al (2012) Results of a randomised phase III trial (EORTC 62012) of single agent doxorubicin versus doxorubicin plus ifosfamide as first line chemotherapy for patients with advanced or metastatic soft tissue sarcoma: a survival study by the EORTC soft tissue and bone sarcoma group. Abstract LBA7. Ann Oncol. doi:10.​1093/​annonc/​mds499
28.
go back to reference Gehl J, Skovsgaard T, Mir LM (1998) Enhancement of cytotoxicity by electropermeabilization: an improved method for screening drugs. Anticancer Drugs 9:319–325PubMedCrossRef Gehl J, Skovsgaard T, Mir LM (1998) Enhancement of cytotoxicity by electropermeabilization: an improved method for screening drugs. Anticancer Drugs 9:319–325PubMedCrossRef
29.
go back to reference Penel N, Van Glabbeke M, Marreaud S, Ouali M, Blay JY, Hohenberger P (2011) Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years. Ann Oncol 22:1266–1272PubMedCrossRef Penel N, Van Glabbeke M, Marreaud S, Ouali M, Blay JY, Hohenberger P (2011) Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years. Ann Oncol 22:1266–1272PubMedCrossRef
30.
31.
go back to reference Jarm T, Cemazar M, Miklavcic D, Sersa G (2010) Antivascular effects of electrochemotherapy: implications in treatment of bleeding metastases. Expert Rev Anticancer Ther 10:729–746PubMedCrossRef Jarm T, Cemazar M, Miklavcic D, Sersa G (2010) Antivascular effects of electrochemotherapy: implications in treatment of bleeding metastases. Expert Rev Anticancer Ther 10:729–746PubMedCrossRef
32.
go back to reference Sleijfer S, Gorlia T, Lamers C et al (2012) Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study. Br J Cancer 107:639–645PubMedCrossRefPubMedCentral Sleijfer S, Gorlia T, Lamers C et al (2012) Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study. Br J Cancer 107:639–645PubMedCrossRefPubMedCentral
33.
go back to reference Rossi CR, Vecchiato A, Mastrangelo G, Montesco MC, Russano F, Mocellin S et al (2013) Adherence to treatment guidelines for primary sarcomas affects patient survival: a side study of the European CONnective TIssue CAncer NETwork (CONTICANET). Ann Oncol 24:1685–1691PubMedCrossRef Rossi CR, Vecchiato A, Mastrangelo G, Montesco MC, Russano F, Mocellin S et al (2013) Adherence to treatment guidelines for primary sarcomas affects patient survival: a side study of the European CONnective TIssue CAncer NETwork (CONTICANET). Ann Oncol 24:1685–1691PubMedCrossRef
Metadata
Title
Electrochemotherapy Treatment of Locally Advanced and Metastatic Soft Tissue Sarcomas: Results of a Non-Comparative Phase II Study
Authors
Luca G. Campana
Giuseppe Bianchi
Simone Mocellin
Sara Valpione
Laura Campanacci
Antonella Brunello
Davide Donati
Elisabetta Sieni
Carlo R. Rossi
Publication date
01-04-2014
Publisher
Springer US
Published in
World Journal of Surgery / Issue 4/2014
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-013-2321-1

Other articles of this Issue 4/2014

World Journal of Surgery 4/2014 Go to the issue